Form D · Biotechnology

Euphrates Vascular, Inc.

St. Louis, MO · CIK 0001752992

Offering snapshot reported Oct 3, 2023 · SEC filing

Reported sold: $9.08M
Investors reported: 33
Minimum accepted: $5K
First sale: Jul 15, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$5,984,167 → $9,084,802

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 3, 2023	Amendment	$9,084,802	$3,100,635vs Jun 1, 2021	33	SEC filing
Jun 1, 2021	Initial	$5,984,167	No comparison	Not reported	SEC filing
Sep 17, 2018	Initial	$590,000	No comparison	4	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $120K
Finders' fees: $0
Form D file number: 021-401265

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
CIM Securities LLC	120852	CIM Securities LLC · CRD 120852

Source: Form D, filed Oct 3, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Martin Omid Akhavan	Director, Executive
Tim Blair	Executive
Jeffrey Blair	Director
Thomas Hillman	Director
Troy Long	Executive
Cathy Matthes	Executive
Robert Mitchell	Director
Eric Moessinger	Director
Sean Morris	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

8460 Watson Road Suite 112
St. Louis, MO, 63119